Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · March 24, 2024

Consistent Glycaemic Efficacy and Safety of Concomitant Use of iGlarLixi and SGLT2 Inhibitor Therapy for Type 2 Diabetes

Diabetes Research and Clinical Practice

 

Additional Info

Diabetes Research and Clinical Practice
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials
Diabetes Res. Clin. Pract. 2024 Mar 05;209(xx)111604, F Giorgino, C Guja, H Aydın, F Lauand, L Melas-Melt, J Rosenstock

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading